It has been a rough five days for Vertex Pharmaceuticals. The FDA placed a partial clinical hold on a key next-generation hepatitis-C drug at the end of last week, and this week's second-quarter earnings were a mixed bag, sending shares lower still.
In this video, health-care analyst David Williamson focuses on VX-135's clinical hold and why investors should be concerned given the drug class' checkered history, but ultimately why it doesn't damage the real reason for owning shares of Vertex.
Rising health care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.
Follow David on Twitter: @MotleyDavid.